Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Pfizer comments on abstract concerning ORAL Sync tofacitinib Phase 3 study in RA

Pfizer Inc. commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis which has been posted for the European League Against Rheumatism conference.

25 Apr 2011

New genetic discovery in Pulmonary Fibrosis

A new discovery in a deadly lung disease may change the direction of research while uncovering increased risk for many patients and families. The Coalition for Pulmonary Fibrosis and the Pulmonary Fibrosis Foundation applaud the efforts of scientists that led to the discovery of a genetic variation associated with the MUC5B gene which may increase the risk of developing Pulmonary Fibrosis.

25 Apr 2011

Study shows neutralizing antibodies against GM-CSF can halt MS development

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model.

25 Apr 2011

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

A new discovery in a deadly lung disease may change the direction of research while uncovering increased risk for many patients and families. The Coalition for Pulmonary Fibrosis (CPF) and the Pulmonary Fibrosis Foundation (PFF) applaud the efforts of scientists that led to the discovery of a genetic variation associated with the MUC5B gene which may increase the risk of developing Pulmonary Fibrosis (PF).

21 Apr 2011

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).

21 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

By identifying a surprising association of two intracellular proteins, University of Iowa researchers have laid the groundwork for the development of new therapies to treat B cell lymphomas and autoimmune disease.

20 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010.

19 Apr 2011

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for review the Company's Biologics License Application for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.

18 Apr 2011

Scientists develop new compound for multiple sclerosis treatment

Scientists from the Florida campus of The Scripps Research Institute have developed the first of a new class of highly selective compounds that effectively suppresses the severity of multiple sclerosis in animal models.

18 Apr 2011

Scientist discovers new molecular mechanism underlying asthma, COPD

Michael Croft, Ph.D., a researcher at the La Jolla Institute for Allergy & Immunology, has discovered a molecule's previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, chronic obstructive pulmonary disease and several other lung conditions.

18 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

JNJ, Merck sign distribution agreement for REMICADE and SIMPONI

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Johnson & Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho Biotech Inc., today announced that the companies have reached agreement to amend the distribution rights to REMICADE and SIMPONI, which treat chronic inflammatory diseases such as rheumatoid arthritis.

15 Apr 2011

Genentech receives FDA approval for Actemra to treat juvenile idiopathic arthritis

The U.S. Food and Drug Administration today approved Actemra, given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis in children ages 2 years and older.

15 Apr 2011

Researchers report injectable gel can help treat arthritis

Some 25 million people in the United States alone suffer from rheumatoid arthritis or its cousin osteoarthritis, diseases characterized by often debilitating pain in the joints. Now researchers at Brigham and Women's Hospital report an injectable gel that could spell the future for treating these diseases and others.

15 Apr 2011

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

PROLOR Biotech, Inc. today reported positive interim efficacy results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone in growth hormone deficient adults.

11 Apr 2011

Amgen acquires Bergamo, expands operations in Brazil

Amgen, the world's largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately-held Brazilian pharmaceutical company.

8 Apr 2011

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye, an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema.

8 Apr 2011

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Pfizer comments on abstract concerning ORAL Sync tofacitinib Phase 3 study in RA

New genetic discovery in Pulmonary Fibrosis

Study shows neutralizing antibodies against GM-CSF can halt MS development

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Prism Pharmaceuticals to be acquired by Baxter

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

Rituxan receives FDA approval for treating two rare diseases

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

Scientists develop new compound for multiple sclerosis treatment

Scientist discovers new molecular mechanism underlying asthma, COPD

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

JNJ, Merck sign distribution agreement for REMICADE and SIMPONI

Genentech receives FDA approval for Actemra to treat juvenile idiopathic arthritis

Researchers report injectable gel can help treat arthritis

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

Amgen acquires Bergamo, expands operations in Brazil

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in